Literature DB >> 21164492

Maternal caffeine intake, blood pressure, and the risk of hypertensive complications during pregnancy. The Generation R Study.

Rachel Bakker1, Eric A P Steegers, Hein Raat, Albert Hofman, Vincent W V Jaddoe.   

Abstract

BACKGROUND: Caffeine intake has been suggested to be associated with the risk of hypertension. Less is known about the associations of caffeine intake on maternal cardiovascular adaptations during pregnancy. We examined the associations of caffeine intake in different trimesters of pregnancy with repeatedly measured blood pressure and the risks of pregnancy-induced hypertension and pre-eclampsia in a population-based cohort of 7,890 pregnant women.
METHODS: In each trimester caffeine intake and systolic and diastolic blood pressure were assessed by questionnaires and physical examinations, respectively. Information about hypertensive complications was obtained from medical records.
RESULTS: Our longitudinal analyses revealed no significant differences for both systolic and diastolic blood pressure. The cross-sectional analyses showed that higher caffeine intake tended to be associated with higher systolic blood pressure in first and third trimester (P trend <0.05), but not in second trimester. Caffeine intake was not consistently associated with diastolic blood pressure levels, or the risk of pregnancy-induced hypertension. As compared to women with caffeine intake of <2 units/day, those using 2-3.9 units/day had a lower risk of pre-eclampsia (odds ratio 0.63 (95% confidence interval: 0.40, 0.96)).
CONCLUSIONS: Higher caffeine intake during pregnancy seems to be associated with elevated systolic blood pressure levels in first and third trimester, but not with diastolic blood pressure levels. We did not find evidence of significant adverse associations of caffeine intake on maternal cardiovascular adaptations during pregnancy. The unexpected finding of a possible protective association with moderate caffeine intake deserves further investigation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21164492     DOI: 10.1038/ajh.2010.242

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  6 in total

1.  The effect of age on the shape of the BMI-mortality relation and BMI associated with minimum all-cause mortality in a large Austrian cohort.

Authors:  R S Peter; B Mayer; H Concin; G Nagel
Journal:  Int J Obes (Lond)       Date:  2014-09-12       Impact factor: 5.095

2.  Antenatal coffee and tea consumption and the effect on birth outcome and hypertensive pregnancy disorders.

Authors:  Timothy van der Hoeven; Joyce L Browne; Cuno S P M Uiterwaal; Cornelis K van der Ent; Diederick E Grobbee; Geertje W Dalmeijer
Journal:  PLoS One       Date:  2017-05-16       Impact factor: 3.240

3.  Hypertensive Disorders of Pregnancy in Relation to Coffee and Tea Consumption: The Japan Environment and Children's Study.

Authors:  Yoko Kawanishi; Aiko Kakigano; Takashi Kimura; Satoyo Ikehara; Takuyo Sato; Takuji Tomimatsu; Tadashi Kimura; Hiroyasu Iso
Journal:  Nutrients       Date:  2021-01-24       Impact factor: 5.717

4.  Assessment of Caffeine Consumption and Maternal Cardiometabolic Pregnancy Complications.

Authors:  Stefanie N Hinkle; Jessica L Gleason; Samrawit F Yisahak; Sifang Kathy Zhao; Sunni L Mumford; Rajeshwari Sundaram; Jagteshwar Grewal; Katherine L Grantz; Cuilin Zhang
Journal:  JAMA Netw Open       Date:  2021-11-01

5.  Prediction of pregnancy-related hypertensive disorders using metabolomics: a systematic review.

Authors:  Jussara Mayrink; Debora F Leite; Guilherme M Nobrega; Maria Laura Costa; Jose Guilherme Cecatti
Journal:  BMJ Open       Date:  2022-04-25       Impact factor: 3.006

6.  Risk factors for RhD immunisation in a high coverage prevention programme of antenatal and postnatal RhIg: a nationwide cohort study.

Authors:  Y M Slootweg; C Zwiers; J M Koelewijn; E van der Schoot; D Oepkes; I L van Kamp; M de Haas
Journal:  BJOG       Date:  2022-03-18       Impact factor: 7.331

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.